Is Now the Right Time to Invest in a Biotech Platform?

Just 8 Days Left, Invest Before the Raise Closes August 27 at $3.00/Share. 

The window before everything changes is usually the one nobody notices, until it closes.

Biotech is one of those sectors people love to say they would’ve invested in earlier:

“I was this close to backing Moderna in 2019, I almost bought Amgen in the ’90s… no, seriously.”

And now? Cytonics is giving investors a shot at something truly rare: A clinical-stage biotech platform still accessible to everyday investors, right before a major value inflection point.

The Reg A+ round closes in just 8 days, on August 27 at 11:59 PM. This is the final chance to invest at $3.00/share before potential future raises at higher valuations.


Phase 1 Is Done. Safely. Cleanly.

That means:

• CYT-108 was successfully delivered to humans
• No drug-related adverse events
• Regulatory greenlights in place
• Valuation has already jumped 753% since the Seed round

We’re no longer in “this might work someday” territory; we’re in “This is real. What’s next?” territory.


Phase 2 Is Where Biotech Value Explodes

This is the stage where:

• Drug efficacy gets tested
• Strategic acquirers start circling
• Licensing deals get made
• And early investors (like you) often see the greatest upside

Sophisticated biotech investors don’t wait until Phase 2 is over. They invest right before it begins, like now.


This Isn’t Just a Product, It’s a Platform

Cytonics isn’t a one-shot company.

They’ve built:

• A recombinant protein engineering platform
• A library of A2M variants
• IP spanning cartilage, inflammation, and protease-driven diseases like: Melanoma, COPD, ARDS, and Chronic wounds

CYT-108 is just the start; this isn’t just an OA treatment. It’s a pipeline in a molecule.


The Timing Couldn’t Be Better

• Biotech valuations are rebounding
• Big Pharma has $1.5 trillion in acquisition firepower
• The FDA is fast-tracking more biologics than ever before
• Cytonics is ready with: A Phase 2-ready asset, 25 issued patents, $25M raised without VC dilution, and a cap table built for upside; not backroom deals

Just 8 Days Left to Join at $3.00/Share

This is your final chance to get in before the raise closes.